Genetic mutations enhance the production of Exotoxin A by <em>Pseudomonas aeruginosa</em> for use as a potential anticancer therapeutic agent

Almami,Ibtesam S.

doi:10.3892/etm.2025.12911

Genetic mutations enhance the production of Exotoxin A by Pseudomonas aeruginosa for use as a potential anticancer therapeutic agent

Authors:
- Ibtesam S. Almami
View Affiliations

Affiliations: Department of Biology, College of Science, Qassim University, Buraydah, Al-Qassim 52571, Saudi Arabia
Published online on: June 23, 2025 https://doi.org/10.3892/etm.2025.12911
Article Number: 161
Copyright: © Almami . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Microbial proteins have emerged as promising anticancer agents for various cancer types. Pseudomonas aeruginosa derived‑Exotoxin A is a potent virulence factor that specifically binds to the α2‑macroglobulin cell receptor. It exhibits strong cytotoxicity and potential advantages over conventional cancer treatments due to its ability to penetrate cancer cell membranes and inhibit protein synthesis. In the present study, 20 P. aeruginosa isolates collected from microbiological laboratories between October 2023 and January 2024 were characterized. The isolates were identified using classical biochemical tests, confirmed using an automated identification system, and classified into six groups based on SDS‑PAGE protein banding patterns. The gene encoding Exotoxin A was amplified in one isolate from each group using PCR, yielding a 367‑bp amplicon. To enhance the production of Exotoxin A, random mutations were introduced to the selected isolates using UV irradiation. Exotoxin A was then purified using column chromatography followed by dialysis, resulting in a product with a molecular mass of ~66 kDa as determined by SDS‑PAGE. The cytotoxic effects of crude and purified Exotoxin A were assessed against the MCF‑7 breast cancer cell line. MTT assay results revealed that the half‑maximal inhibitory concentration (IC₅₀) of purified Exotoxin A from a wild‑type isolate was 4.9 µg/ml, whereas the corresponding mutant exhibited an IC₅₀ of 3.6 µg/ml, indicating a 1.4‑fold increase in cytotoxic activity. The findings of the present study highlight the potential of microbial‑derived proteins in cancer therapy. However, further evaluation of these proteins is necessary to explore their therapeutic applicability.

View Figures

View References

1	Washington JA: Principles of Diagnosis in Baron's Medical Microbiology (Baron S), 4th Edition, Chapter 10, 1996. Available from: http://www.ncbi.nlm.nih.gov/books/NBK8014/.
2	Palleroni NJ and Moore ERB: Taxonomy of pseudomonads: Experimental approaches. In: Pseudomonas, 2004.
3	Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, Liang H, Song X and Wu M: Pseudomonas aeruginosa: Pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther. 7(199)2022.PubMed/NCBI View Article : Google Scholar
4	Lu S, Chen K, Song K, Pilewski JM, Gunn BM, Poch KR, Rysavy NM, Vestal BE, Saavedra MT and Kolls JK: Systems serology in cystic fibrosis: Anti-Pseudomonas IgG1 responses and reduced lung function. Cell Rep Med. 4(101210)2023.PubMed/NCBI View Article : Google Scholar
5	Do Rego H and Timsit JF: Management strategies for severe Pseudomonas aeruginosa infections. Curr Opin Infect Dis. 36:585–595. 2023.PubMed/NCBI View Article : Google Scholar
6	Ren Y, Zhu R, You X, Li D, Guo M, Fei B, Liu Y, Yang X, Liu X and Li Y: Quercetin: A promising virulence inhibitor of pseudomonas aeruginosa LasB in vitro. Appl Microbiol Biotechnol. 108(57)2024.PubMed/NCBI View Article : Google Scholar
7	Ryan KJ, Ray CG, Ahmad N, et al: Sherris Medical Microbiology 6th edition, 2014.
8	Liao C, Huang X, Wang Q, Yao D and Lu W: Virulence factors of pseudomonas aeruginosa and antivirulence strategies to combat its drug resistance. Front Cell Infect Microbiol. 12(926758)2022.PubMed/NCBI View Article : Google Scholar
9	Casas V and Maloy S: Role of bacteriophage-encoded exotoxins in the evolution of bacterial pathogens. Future Microbiol. 6:1461–1473. 2011.PubMed/NCBI View Article : Google Scholar
10	Gellatly SL and Hancock REW: Pseudomonas aeruginosa: New insights into pathogenesis and host defenses. Pathog Dis. 67:159–173. 2013.PubMed/NCBI View Article : Google Scholar
11	Balasubramanian D, Schneper L, Kumari H and Mathee K: A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence. Nucleic Acids Res. 41:1–20. 2013.PubMed/NCBI View Article : Google Scholar
12	Gholami A, Minai-Tehrani D, Mahdizadeh SJ, Saenz-Mendez P and Eriksson LA: Structural insights into pseudomonas aeruginosa exotoxin A-elongation factor 2 interactions: A molecular dynamics study. J Chem Inf Model. 63:1578–1591. 2023.PubMed/NCBI View Article : Google Scholar
13	Yarahmadi A, Zare M, Aghayari M, Afkhami H and Jafari GA: Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: New insights for future. Cell Commun Signal. 22(239)2024.PubMed/NCBI View Article : Google Scholar
14	Guo L, Ding J and Zhou W: Harnessing bacteria for tumor therapy: Current advances and challenges. Chinese Chemical Letters. 35(108557)2024.
15	Morgan RN, Saleh SE, Farrag HA and Aboshanab KM: New insights on Pseudomonas Aeruginosa exotoxin A-based immunotoxins in targeted cancer therapeutic delivery. Ther Deliv. 14:31–60. 2023.PubMed/NCBI View Article : Google Scholar
16	Gao M, Zhou J, Su Z and Huang Y: Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy. Protein Science. 26:2334–2341. 2017.PubMed/NCBI View Article : Google Scholar
17	Chakrabarty AM: Microbial pathogenicity: A new approach to drug development. Adv Exp Med Biol. 808:41–49. 2014.PubMed/NCBI View Article : Google Scholar
18	Benson RF, Tang PW and Fields BS: Evaluation of the Binax and Biotest urinary antigen kits for detection of Legionnaires' disease due to multiple serogroups and species of Legionella. J Clin Microbiol. 38:2763–2765. 2000.PubMed/NCBI View Article : Google Scholar
19	Bannoehr J, Franco A, Iurescia M, Battisti A and Fitzgerald JR: Koneman. Koneman's color atlas and textbook of diagnostic microbiology. J Clin Microbiol. 47:469–471. 2009.
20	Greenwood D, Slack R and Peutherer JF: A guide to microbial infections, pathogenesis, immunity, laboratory diagnosis and control. In: Medical Microbiology. ThriftBooks-Phoenix, Tolleson, AZ, 2006.
21	Khan AA and Cerniglia CE: Detection of pseudomonas aeruginosa from clinical and environmental samples by amplification of the exotoxin A gene using PCR. Appl Environ Microbiol. 60:3739–3745. 1994.PubMed/NCBI View Article : Google Scholar
22	Trovão M, Schüler LM, Machado A, Bombo G, Navalho S, Barros A, Pereira H, Silva J, Freitas F and Varela J: Random mutagenesis as a promising tool for microalgal strain improvement towards industrial production. Mar Drugs. 20(440)2022.PubMed/NCBI View Article : Google Scholar
23	Bose JL: Chemical and UV mutagenesis. Methods Mol Biol. 1373:111–115. 2014.PubMed/NCBI View Article : Google Scholar
24	Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680–685. 1970.PubMed/NCBI View Article : Google Scholar
25	Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983.PubMed/NCBI View Article : Google Scholar
26	Vijayan P, Raghu C, Ashok G, Dhanaraj SA and Suresh B: Antiviral activity of medicinal plants of Nilgiris. Indian J Med Res. 120:24–29. 2004.PubMed/NCBI
27	Yang Q, Wang B, Zheng Q, Li H, Meng X, Zhou F and Zhang L: A review of gut microbiota-derived metabolites in tumor progression and cancer therapy. Adv Sci (Weinh). 10(e2207366)2023.PubMed/NCBI View Article : Google Scholar
28	Masuyer G: Crystal structure of exotoxin A from aeromonas pathogenic species. Toxins (Basel). 12(397)2020.PubMed/NCBI View Article : Google Scholar
29	Aljebory IS: PCR detection of some virulence genes of pseudomonas aeruginosa in Kirkuk city, Iraq. J Pharm Sci Res. 10:1068–1071. 2018.
30	Ismail YM, Fayed SM, Elesawy FM, El-Halim NZA and El-Shimi OS: Phenotypic and molecular characteristics of pseudomonas aeruginosa isolated from burn unit. Egyptian Journal of Medical Microbiology (Egypt). 30:19–28. 2021.
31	Bourdenet S, Doyonnas R, Vacheron MJ, Guinand M, Fasciotto B, Ristic A, Michel G, Cozzone AJ, Durkin JP and Whitfield JF: The cytotoxicity of Pseudomonas exotoxin A, inactivated by modification of the cell-binding domain I, is restored when conjugated to an erythroid cell-specific targeting agent. Cancer Lett. 50:121–127. 1990.PubMed/NCBI View Article : Google Scholar
32	Gallant CV, Raivio TL, Olson JC, Woods DE and Storey DG: Pseudomonas aeruginosa cystic fibrosis clinical isolates produce exotoxin A with altered ADP-ribosyltransferase activity and cytotoxicity. Microbiology (NY). 146:1891–1899. 2000.PubMed/NCBI View Article : Google Scholar
33	Prinsloo S, Pieters R and Bezuidenhout CC: A cell viability assay to determine the cytotoxic effects of water contaminated by microbes. S Afr J Sci. 109:1–4. 2013.
34	Wolf P, Alt K, Bühler P, Katzenwadel A, Wetterauer U, Tacke M and Elsässer-Beile U: Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice. Prostate. 68:129–138. 2008.PubMed/NCBI View Article : Google Scholar
35	Panahi Z, Owrang M and Goli HR: Significant role of pyocyanin and exotoxin A in the pathogenesis of pseudomonas aeruginosa isolated from hospitalized patients. Folia Med (Plovdiv). 66:88–96. 2024.PubMed/NCBI View Article : Google Scholar